Every day, communities across the world are being impacted by heavy metal poisoning. Lead paint in homes, leaded water lines, and lead batteries are ever-present. Radioactive material from power plants or a nuclear disaster place much of the world’s population at risk of contamination. When we encounter heavy metals in foods, drugs, medical treatments, or the environment, we risk lifelong health consequences. In all of these cases, safe and effective treatments for people who have been exposed are currently non-existant. Our Focus Areas
HOPO Therapeutics leverages our world-class expertise to address the most pressing unmet needs at the intersection of heavy metals and human health. For us, the term “heavy metals” includes environmental pollutants like lead, cadmium, arsenic, and mercury, as well as the lanthanide elements, many of which are considered critical materials for energy and technology applications. We also include the radioactive actinide elements that drive our nuclear power plants, medical technologies, space vehicles, and nuclear weapons.
We are developing pharmaceuticals designed to treat exposure to heavy metals, beginning with our flagship drug candidate HOPO-101, now in clinical development.